Guide
Tirzepatide 3-Month Plans: What the Middle Term Actually Saves
A three-month plan on the programme we captured is $195 a month against $215 month-to-month — a $60 saving over the quarter, about 9%. It also commits you through the tit
A three-month plan on the programme we captured is $195 a month against $215 month-to-month — a $60 saving over the quarter, about 9%. It also commits you through the titration window, which is when most discontinuation happens.
What does the comparison actually show?
| Term | Monthly | Plan total | Saving vs monthly | Payment |
|---|---|---|---|---|
| Month-to-month | $215 | — | — | Cancel before the next cycle |
| 3-month | $195 | $585 | $60 | Paid up front |
| 6-month | $190 | $1,140 | $150 | Paid up front |
| 12-month | $186 | $2,232 | $348 | Paid up front |
Three months is almost exactly the titration window. In SURMOUNT-1, between 4.3% and 7.1% of participants discontinued for an adverse event, and that happens during escalation.
A $60 saving is a poor trade if you stop in week six and recover nothing. Ask what is refunded before you prepay — and separately, what happens to a prepaid balance if supply is interrupted, because the 503B bulks proposal is unresolved.
The three-month term is the reasonable compromise for most people: enough discount to matter, short enough that a bad tolerability outcome does not strand a year of money.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What did we capture, and where?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How much does a 3-month tirzepatide plan cost?
$195 a month, $585 for the quarter, on the programme we captured — a $60 saving against paying monthly.
Is a longer plan better value?
The twelve-month plan saves $348 a year, about 13%. It also commits you through the window when most discontinuation happens.
What should I ask before prepaying?
What is refunded if you stop, and separately what happens to a prepaid balance if supply is interrupted.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- PlushCare Tirzepatide ReviewProviders
- NexLife vs Ro BodyComparisons
- NexLife vs Hims & HersComparisons
- Mounjaro vs ZepboundPillar / Money
- Hims & Hers Tirzepatide ReviewProviders
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Brand-Name vs Compounded GLP-1Comparisons
Related coverage
GLP-1 Tirzepatide Rank. “Tirzepatide 3-Month Plans: What the Middle Term Actually Saves.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-3-month-plan-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.